Login to Your Account



Pharma: Clinic Roundup


Wednesday, September 25, 2013
• Janssen Research and Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said results from a 52-week analysis of a Phase III trial of Invokana (canagliflozin) showed substantial improvements in glycemic control for patients with Type II diabetes who are inadequately controlled on metformin and a sulfonylurea therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription